IP Verse

Polpharma competitive analysis

Explore the latest publications and patents granted to Polpharma, showcasing their recent innovations and technological advancements.

Explore patent oppositions filed by Polpharma against competitors, revealing strategic technology disputes and market positioning.

Last updated on: Oct 2, 2025

Patent Number	Title	Applicant	Opposition Date
Get instant updates on new opposition filings by the company
EP4152004	Assay For Jc Virus Antibodies	BIOGEN MA	Aug 19, 2025
EP4321157	New Use Of A Combination Of An Angiotensin Receptor Blocker (Arb) With A Neutral Endopeptidase Inhibitor (Nepi)	NOVARTIS	Jul 23, 2025
EP3237004	Predicting Outcome Of Treatment With An Anti- 4 7 Integrin Antibody	MILLENNIUM PHARMACEUTICALS	Feb 7, 2025
EP3529360	Methods For Preventing Cardiovascular Events Through Proprotein Convertase Subtilisin Kexin 9 (Pcsk9) Protein Reduction	NOVARTIS	Jan 15, 2025
EP3474820	Glp-1 Compositions And Uses Thereof	NOVO NORDISK	Nov 7, 2024
EP2395968	Pharmaceutical Composition Comprising Glucopyranosyl Diphenylmethane Derivatives, Pharmaceutical Dosage Form Thereof, Process For Their Preparation And Uses Thereof For Improved Glycemic Control In A Patient	BOEHRINGER INGELHEIM	Oct 10, 2024
EP3595667	Pharmaceutical Compositions Comprising A Jak Inhibitor	ALFASIGMA	Sep 20, 2024
EP3999643	Methods Of Treating Or Preventing Spinal Muscular Atrophy	BIOGEN MA	Aug 20, 2024
EP3270909	Fixed Dose Combinations Comprising Etc1002 And One Or More Statins For Treating Or Reducing Cardiovascular Risk	ESPERION THERAPEUTICS	Jul 31, 2024
EP3626270	New Use	NOVARTIS	Jul 10, 2024

Discover the latest PTAB cases involving Polpharma, highlighting their recent legal challenges and patent disputes.

IP litigation analysis comparing Polpharma with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Oct 2, 2025

Company	Oppositions Filed	Oppositions Faced	PTAB Cases Filed	PTAB Cases Faced	Strategy Type
PHARMACEUTICAL WORKS POLPHARMA	3	-	-	-	Highly Aggressive
BIOGEN IDEC MA	-	29	-	1	Non-Active
BIOGEN MA	-	51	-	7	Non-Active
ELAN PHARMACEUTICALS	-	3	-	-	Non-Active